Pediatrics

Pharmacists can help familiarize young patients with the vaccinations appropriate for pediatric use.

Phase 3 study follows recent approval of the drug for the same condition in individuals aged 12 years and older who weight at least 40 kg.

Individuals randomized to receive dabrafenib and trametinib had a statistically significant overall response rate of 47% compared with 11% for those who received chemotherapy.

Case highlights the need to stop, listen, and investigate when patients or parents express a safety concern.

Approximately one-third of parents said their children are picky, and another third said they don’t think their children eat enough fruits and vegetables.

Analysis provides new understanding of the effect of probiotics on the tiniest of infants in the neonatal intensive care.

Analysis shows the activity of a specific enzyme, Butyrylcholinesterase, was significantly lower in those who subsequently died of sudden infant death syndrome.

Investigators develop a genetic-risk score to identify those who would benefit most from lifestyle counseling to prevent the condition.

Second analysis indicates that parents of children with food allergies became less anxious during the pandemic.

Educating patients can be especially rewarding with children.

Data from the study shows a strong immune response in this age group following this dose, with no new safety signals.

The PREVENT-19 study evaluates the immunogenicity and safety of a third dose of NVX-CoV2373 in children aged 12 to 17 years.

Three in 5 say it is hard to get kids to eat well-balanced diets, because of not eating enough fruits and vegetables, pickiness, and other reasons.

Analysis assessing data from the world’s largest twin registry also finds evidence that genetic factors for strong headaches may differ between men and women.

The medication is the first oral therapy specifically to treat the virus evaluated in a pediatric clinical trial.

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.

The investigators identified this in 9% of relapsed cases of pediatric acute myeloid leukemia, but it also was present in primary samples.

New study results show that rapidly adding pounds in the first and final months of gestation likely plays a key role in the development of excess fat tissue in female children and adolescents.

New study results show that of those who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms.

Study results show that unvaccinated pregnant women with the disease are more likely to experience poor childbirth outcomes, even if they did not have severe respiratory problems.

Study data showed that increased levels of infection, inflammation, and metabolic alterations frequently observed in people with depression and psychosis may be a cause rather than a consequence of these disorders.

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

GeneSight Mental Health Monitor finds that many struggle to know the difference between teenage behavior and a mental health challenge.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

Study results show that fetal cognitive development in the assessed areas was age-appropriate and there was no indication of infection.

Lomecel-B (Longeveron) is an investigational allogeneic, bone marrow-derived medicinal signaling cell medication that is being evaluated in a phase 2 trial.

In a report, the World Health Organization and a partner ask developers, funders, and investigators to accelerate developing a vaccination.

Study shows that about half the pediatric cases were symptomatic compared with 88% for individuals aged 18 years and older.